β-arrestins的形态灵活性 - 这些支架蛋白如何指导和改变GPCRs的功能
Raphael S Haider1,2,3, Mona Reichel1, Edda S F Matthees1
1Institut für Molekulare Zellbiologie, CMB - Center for Molecular Biomedicine, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Hans-Knöll-Straße 2, Jena, Germany.
概括
β-阿雷斯作为多功能支架,通过与各种受体相互作用来调解多种细胞功能. 这项研究假设GPCRs如何诱导特定的β-arrestin形态形成不同的信号复合体.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 结构生物学 结构生物学
背景情况:
- G蛋白结合受体 (GPCRs) 是关键的跨膜蛋白调节细胞功能.
- β-阿雷斯是关键的细胞内信号传感器,它们与GPCRs结合.
- β-阿雷斯招募效应体,形成影响GPCR信号特异性的信号复合体.
研究的目的:
- 阐明活性GPCRs在β-arrestins中诱导特定形状变化的机制.
- 了解这些形状变化如何导致不同的效应子集的招募.
- 探索β-arrestin多方面的支架作用的功能影响.
主要方法:
- 先进的结构方法先进的结构方法.
- 新型生物传感器开发开发.
- 互动组分析互动组分析.
主要成果:
- 由GPCR诱导的β-arrestin形态重组的假设机制.
- 在β-arrestins上识别不同的结合接口.
- 由β-arrestins介导的专门信号复合物的形成.
结论:
- β-阿雷斯是GPCR信号传递至关重要的多面架构蛋白质.
- 为了实现信号特异性,GPCRs决定了β-逮捕的合规性.
- 需要进一步的研究,以全面评估β-阿雷斯的结构状态和功能.
相关概念视频
GPCR Desensitization
6.2K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.2K
Activation and Inactivation of G Proteins
7.3K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
7.3K
Assembly of Signaling Complexes
5.8K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
5.8K
GPCRs Regulate Adenylyl Cylase Activity
5.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Transducer Mechanism: G Protein–Coupled Receptors
2.1K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
2.1K


